Vestmark Advisory Solutions Inc. bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 472,256 shares of the company's stock, valued at approximately $4,656,000. Vestmark Advisory Solutions Inc. owned approximately 0.22% of Recursion Pharmaceuticals at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in RXRX. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock worth $203,651,000 after purchasing an additional 13,777,689 shares during the last quarter. FMR LLC raised its stake in Recursion Pharmaceuticals by 134.4% during the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company's stock valued at $81,775,000 after acquiring an additional 6,129,935 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Recursion Pharmaceuticals by 161.2% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company's stock valued at $90,749,000 after acquiring an additional 5,680,656 shares in the last quarter. Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals by 37.7% during the 3rd quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company's stock valued at $118,627,000 after acquiring an additional 4,247,002 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its stake in Recursion Pharmaceuticals by 244.7% during the 3rd quarter. Rafferty Asset Management LLC now owns 1,104,526 shares of the company's stock valued at $8,450,000 after acquiring an additional 784,113 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.
Insider Buying and Selling
In related news, CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total value of $175,279.92. Following the transaction, the chief financial officer now directly owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total value of $119,120.00. Following the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at approximately $9,529,331.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total value of $175,279.92. Following the transaction, the chief financial officer now owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The disclosure for this sale can be found here. Insiders have sold 412,665 shares of company stock worth $4,036,978 in the last three months. 19.96% of the stock is currently owned by insiders.
Recursion Pharmaceuticals Price Performance
Shares of RXRX traded up $0.05 during midday trading on Friday, reaching $8.84. The stock had a trading volume of 3,982,474 shares, compared to its average volume of 4,073,535. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.80 and a 52 week high of $16.75. The firm's 50 day moving average price is $9.88 and its 200-day moving average price is $9.18. The company has a market capitalization of $2.07 billion, a P/E ratio of -5.70 and a beta of 0.85.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06. The company had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have weighed in on RXRX shares. TD Cowen started coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a "market perform" rating on the stock. KeyCorp lifted their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Monday, March 4th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $12.75.
Read Our Latest Research Report on RXRX
About Recursion Pharmaceuticals
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
